Nicotine - People Living With Disabilities: Difference between revisions
created page |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
<br> | <br> | ||
=SMOKING INITIATION= | ='''SMOKING INITIATION'''= | ||
===2026: [https://www.sciencedirect.com/science/article/pii/S0306460325003570 Functional disability and the risk of subsequent smoking initiation: A prospective cohort analysis]=== | ===2026: [https://www.sciencedirect.com/science/article/pii/S0306460325003570 Functional disability and the risk of subsequent smoking initiation: A prospective cohort analysis]=== | ||
| Line 10: | Line 10: | ||
*** Acknowledgments: This research was conducted independently without funding from any specific grant or organization. The open access publication fee was covered by the University of Glasgow through their agreement with Elsevier. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. | *** Acknowledgments: This research was conducted independently without funding from any specific grant or organization. The open access publication fee was covered by the University of Glasgow through their agreement with Elsevier. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. | ||
=SMOKING PREVALENCE and DISPARITIES= | ='''SMOKING PREVALENCE and DISPARITIES'''= | ||
=SMOKING CESSATION= | ='''SMOKING CESSATION'''= | ||
===2013: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/ A fresh look at tobacco harm reduction: the case for the electronic cigarette]=== | ===2013: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/ A fresh look at tobacco harm reduction: the case for the electronic cigarette]=== | ||
| Line 23: | Line 23: | ||
***Acknowledgments: R.P. is Professor of Medicine and he is supported by the University of Catania, Italy. He has received lecture fees and research funding from GlaxoSmithKline and Pfizer, manufacturers of stop smoking mediactions. He has also served as a consultant for Pfizer and Arbi Group Srl (Milano, Italy), the distributor of Categoria™ e-Cigarettes. R.P.’s research on electronic cigarettes is currently supported by LIAF (Lega Italiana AntiFumo). B.R.’s research is supported by unrestricted grants from tobacco manufacturers to the University of Louisville, and by the Kentucky Research Challenge Trust Fund. P.C. and C.R. are Assistant Professors and they are supported by the University of Catania, Italy. M.M is researcher and she is supported by the University of Catania, Italy. They have no relevant conflict of interest to declare in relation to this work. | ***Acknowledgments: R.P. is Professor of Medicine and he is supported by the University of Catania, Italy. He has received lecture fees and research funding from GlaxoSmithKline and Pfizer, manufacturers of stop smoking mediactions. He has also served as a consultant for Pfizer and Arbi Group Srl (Milano, Italy), the distributor of Categoria™ e-Cigarettes. R.P.’s research on electronic cigarettes is currently supported by LIAF (Lega Italiana AntiFumo). B.R.’s research is supported by unrestricted grants from tobacco manufacturers to the University of Louisville, and by the Kentucky Research Challenge Trust Fund. P.C. and C.R. are Assistant Professors and they are supported by the University of Catania, Italy. M.M is researcher and she is supported by the University of Catania, Italy. They have no relevant conflict of interest to declare in relation to this work. | ||
=STIGMA= | ='''EXCLUSION FROM RESEARCH'''= | ||
='''STIGMA'''= | |||
===2019: [https://www.jto.org/article/S1556-0864(19)30813-5/fulltext ES13.05 Stigma and Impact of Tobacco Control Policy]=== | ===2019: [https://www.jto.org/article/S1556-0864(19)30813-5/fulltext ES13.05 Stigma and Impact of Tobacco Control Policy]=== | ||
| Line 32: | Line 34: | ||
**Citation: Borondy Kitts, A. (2019). ES13.05 stigma and impact of tobacco control policy [Conference abstract]. Journal of Thoracic Oncology, 14(10 Suppl.), S48–S49. https://doi.org/10.1016/j.jtho.2019.08.130 | **Citation: Borondy Kitts, A. (2019). ES13.05 stigma and impact of tobacco control policy [Conference abstract]. Journal of Thoracic Oncology, 14(10 Suppl.), S48–S49. https://doi.org/10.1016/j.jtho.2019.08.130 | ||
=THERAPEUTIC BENEFITS= | ='''THERAPEUTIC BENEFITS'''= | ||
===Please see this page: [https://safernicotine.wiki/mediawiki/index.php/Nicotine%20therapeutic%20benefits Nicotine therapeutic benefits]=== | ===Please see this page: [https://safernicotine.wiki/mediawiki/index.php/Nicotine%20therapeutic%20benefits Nicotine therapeutic benefits]=== | ||